Acrux Limited (AU:ACR) has released an update.
Acrux Limited has announced FDA approval for its generic Dapsone Gel, 7.5%, marking the company’s fifth ANDA success for a topical acne treatment. With the green light from the FDA, Acrux is poised to tap into the U.S. market where the annual sales for such acne treatments exceed $37.4 million. This milestone underscores Acrux’s expertise in developing complex topical products and expands its presence in the pharmaceutical sector.
For further insights into AU:ACR stock, check out TipRanks’ Stock Analysis page.
